The agreements are to distribute RainDance's products in Central and Eastern Europe, Italy, Switzerland, Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.
Several early-access customers presented results from the 10X technology at the meeting.
The firm said that it plans to list its stock on the Nasdaq under ticker symbol "RAIN" and added that its 2014 revenues were up 78 percent year over year to $30.6 million.
Bio-Rad reported $598.2 million in revenues for the quarter, down from $602.6 million a year ago but surpassing the average analysts' estimate of $593.4 million.
The plaintiffs accuse 10X, a synthetic long-read technology firm, of infringing six patents covering methods of conducting reactions within microfabricated substrates.
The research may prove relevant to understanding human diversity as well as the genetic underpinning of certain CNV-related disorders.
An increasing number of publications using droplet-based digital PCR platforms suggests acceptance and uptake of the technology.
The company plans to launch a PCR-based test for measuring three genes in the plasma of lung cancer patients and is also at work on an NGS-based panel.
Officials from Exact Sciences, Cepheid, Bio-Rad, Biocartis, and NanoString provided strategic updates at the conference.
Trends included expanding test menus and a possible tipping point for point-of-care.
Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.
Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.
Slate's Jane Hu compares some at-home genetic tests to astrology.
In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.